Aarti Pharmalabs gets ₹59.5 crore stamp duty order (2026)

What the latest disclosure says

Aarti Pharmalabs Ltd reported that it has received an order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat. The order is dated August 29, 2026, and relates to adjudication of stamp duty and penalties connected to a past corporate restructuring. As per the disclosure carried under Regulation 30 of SEBI (LODR), the total amount assessed is ₹59.50 crore. Reuters also reported the development on September 2, 2026, stating that total stamp duty and penalties amount to 595 million rupees. The company has indicated it intends to challenge the order.

Who issued the order and the legal framework cited

The order was issued by the Office of the Superintendent of Stamps, Gandhinagar, Gujarat. The disclosure references Chapter IV of the Gujarat Stamp Act, 1958. The matter relates to stamp duty adjudication and associated penalties, which can arise when an authority concludes there has been a short payment or non-payment of duty. The company has positioned the issue as a dispute linked to interpretation and applicability to its transaction. It has also stated it is evaluating the order on facts and law. The disclosure notes it was awaiting the physical copy dispatched via registered post at the time of intimation.

What the demand comprises: duty and multiple penalties

Aarti Pharmalabs said the total assessed amount aggregates to ₹59.50 crore, comprising stamp duty and penalties. The break-up provided in the disclosure includes stamp duty of ₹25 crore under Article 20(D) of Schedule-I of the Gujarat Stamp Act, 1958. It also includes a penalty equal to the deficient duty of ₹25 crore as per Rule 9 of the Mumbai Stamp (Market Value Determination) Rules, 1984, as cited in the disclosure. In addition, an extra penalty of ₹9.50 crore has been levied under the Gujarat Stamp Act, 1958. Together, these components sum to ₹59.50 crore, aligning with Reuters’ figure of 595 million rupees.

Link to the 2022 demerger scheme with Aarti Industries

The dispute is tied to the Scheme of Arrangement (Demerger) between Aarti Industries Limited and Aarti Pharmalabs Limited. The scheme was sanctioned by the National Company Law Tribunal (NCLT), Ahmedabad Bench, on September 21, 2022. The stamp duty order pertains to the adjudication of duty on this NCLT-approved scheme, as cited in the company’s disclosure. Such schemes typically involve transfer of assets and liabilities and can draw stamp duty implications depending on state law interpretation. The company’s update frames the authority’s allegation as short payment or non-payment of stamp duty linked to the scheme.

Company response: intent to contest the order

Aarti Pharmalabs stated it believes it has a strong case on merits and plans to challenge the order. Management indicated it would pursue appropriate actions based on what it described as adequate factual and legal grounds. The company’s disclosure signals the matter is at an evaluation stage rather than an accepted liability. It also noted the date of receipt or awareness of the direction as September 1, 2026, while waiting for the physical order copy. Beyond the intent to challenge, the disclosure does not quantify any provisioning or cash impact.

FY26 snapshot and stated growth targets

Separately, the provided update includes FY26 standalone performance indicators. Standalone revenue for FY26 is stated at ₹17,976 million, up 1.5% year-on-year. Standalone profit after tax (PAT) is stated at ₹1,762 million, down 31.5% year-on-year. Standalone EBITDA margin is stated at 22.59%, down 149 basis points year-on-year. The same note mentions a target of 15% to 18% revenue and EBITDA CAGR over the next 3 to 4 years, positioned as an internal target. The update also references a market capitalisation figure of ₹7,675.59 crore.

Corporate actions and calendar items disclosed

The company is stated to have declared a 40% dividend, with an ex-date of September 15, 2026. In a separate line item, a board meeting initially scheduled for May 18, 2026 was revised to May 25, 2026, with the meeting rescheduled accordingly. These disclosures are typically monitored by investors because they can affect near-term trading (for dividends) and the timing of results or other board decisions (for meeting dates). The text does not provide additional details on the agenda for the rescheduled meeting.

Market impact: what investors can measure from disclosed numbers

The disclosed stamp duty and penalty order totals ₹595 million, a measurable figure that investors can compare against earnings and cash flows. FY26 standalone PAT is stated at ₹1,762 million, which provides a reference point for the size of the demand relative to annual profitability. The disclosure also clearly states the company’s intention to challenge the order, so the amount is presented as a disputed claim rather than a settled obligation. On the operating side, the update highlights margin contraction of 149 bps year-on-year to 22.59% and a 31.5% decline in FY26 standalone PAT, which are directly comparable performance indicators. The 40% dividend announcement, with ex-date September 15, 2026, is a separate event that may influence stock activity around the record and ex-date window.

Key facts table

Why the episode matters

Stamp duty disputes linked to court-approved schemes can become material because they involve state-level interpretation and penalties that can increase the headline number. Here, the total demand includes multiple penalties, taking the aggregate to ₹595 million. The company’s stated stance is that it has strong grounds to contest the order, which means the next set of disclosures could revolve around legal filings, hearings, or revised assessments. Separately, the FY26 snapshot shows a decline in profitability and margin versus the previous year, which investors may read alongside any contingent liabilities. The next concrete update will likely be the company’s formal challenge process and any subsequent regulatory or legal communications, if filed or admitted.